VIT 100

Drug Profile

VIT 100

Alternative Names: ChelASE; ProliferASE

Latest Information Update: 22 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immusol
  • Developer iTherX Pharmaceuticals
  • Class Antipsoriatics; Eye disorder therapies; Skin disorder therapies
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Glaucoma; Hypertrophic scars; Keloids; Proliferative vitreoretinopathy; Psoriasis

Most Recent Events

  • 24 Aug 2007 This programme is still in active development
  • 15 Apr 2003 Phase-I clinical trials in Hypertrophic scars in USA (Topical)
  • 15 Apr 2003 Phase-I clinical trials in Keloids in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top